Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from JJ.

These 2 Healthcare Stocks Are Even Better Bargain Buys Than UnitedHealth

As the healthcare sector lags broader markets, AbbVie’s innovation in immunology and Johnson & Johnson’s MedTech expansion make these dividend giants standout bargains at below-market valuations

Barchart

J&J Commits $2 Billion To US Manufacturing Expansion Amid Threat Of Drug Tariffs

Johnson Johnson (NYSE:JNJ) is set to invest $2 billion in its North Carolina facilities, expanding its U.S. manufacturing operations. This move comes in response to potential drug import tariffs proposed by the Trump administration.

Benzinga

“Impressive value for guitarists seeking rich clean/overdrive tones and timeless distortion tones”: PRS Archon Classic Head review

The PRS Archon Classic runs the gamut from crystal cleans to classic crunch and hot-rodded high gain

Guitar World

From analysis to the latest developments in health,
read the most diverse news in one place.

2 Recession-Proof Dividend Stocks to Buy for the Second Half of 2025

These blue-chip stocks offer a rare combination of stability, resilience, and moderate growth.

Barchart

Stock Of The Day: Breakout In Johnson & Johnson

Johnson Johnson (NYSE:JNJ) stalled out at resistance around the $165 level. There tends to be resistance at price levels that had previously been resistance. As you can see on the chart below, that's the case here. This level was also resistance in March.

Benzinga

Tylenol parent Kenvue has a new CEO, and he has lots of work to do to mollify activist investors

The company will likely focus on off-loading smaller beauty brands.

Fortune

6 Stocks to Buy to Give Your Portfolio the Perfect Mix of Growth, Value, and Defense

This blend of stocks may be the key to long-term success.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Build a Bulletproof Dividend Portfolio With These 5 Defensive Stocks

These defensive stocks pay reliable dividends.

Barchart

J&J Snack Foods Hits New 52-Week Low: Time to Buy?

Among the 96 Nasdaq stocks hitting new 52-week lows Tuesday was the New Jersey-based manufacturer of snack foods and frozen beverages. The small-cap stock hit its 10th new 52-week low over the past 12 months. Time to buy?

Barchart

UnitedHealth spent $1.7 million on executive security last year, 4 times the corporate average. Experts expect the figure to keep climbing

UnitedHealth Group reported its executive security compensation months after the CEO of health insurance arm UnitedHealthcare was fatally shot in December.

Fortune

3 Dividend Stocks to Buy for a Safe Haven in This Volatile Market

The consistency in their dividend payments makes them dependable stocks in a volatile market.

Barchart

Johnson & Johnson begins battle over baby powder’s ‘link to cancer’ in $10 billion case

Courts have rejected J&J’s two previous efforts to resolve the talc litigation

The Independent UK

Slush Puppie’s Parent Hits 52-Week Low. Time to Buy?

J&J Snack Foods, the maker of food and beverage brands such as Slush Puppie, SuperPretzel, and Hola Churros, hit a 52-week low on Tuesday, its 14th in the past 12 months. Here’s why it’s time to buy.

Barchart

Thousands to sue Johnson & Johnson in UK over alleged talc link to cancer

Group action with 3,500 claimants alleges company knew its talcum powder products contained dangerous asbestos

The Guardian - UK

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

2 Dividend Kings You Should Snap Up Immediately

Recent earnings from these dividend-paying companies reflects their stability.

Fortune

How tech leaders are rethinking their cloud strategies in the face of fast-rising costs

As spending on cloud computing rises sharply amid the generative AI boom, executives are on the hunt for cost savings.

The Independent UK

J&J buys Intra-Cellular in $14.6 billion deal, delving further into central nervous system disorders

Johnson & Johnson will spend more than $14 billion to move deeper into treating central nervous system disorders by purchasing Intra-Cellular Therapies

The Independent UK

‘I felt betrayed’: Woman blames cancer diagnosis on talcum powder use

Exclusive: Jane Campbell is one of thousands of women in the UK planning legal action against one of the world’s largest pharmaceutical firms over alleged links between talc and cancer

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

FDA proposes new testing rules to ensure cosmetics are asbestos-free

The Food and Drug Administration is proposing a rule that cosmetic companies would have to take extra steps to ensure that any products containing talc are free of asbestos

International Business Times UK

Burning Concerns: New Study Links Scented Candles to Increased Cancer Risks

Recent studies show scented candles may emit harmful substances that can lead to respiratory problems and cognitive decline.

International Business Times

Johnson & Johnson Risks UK Lawsuit Over Talc Cancer Claim

UK claimants announced Wednesday legal action against US pharmaceutical and cosmetics giant Johnson & Johnson, alleging that women diagnosed with cancers were exposed to asbestos in the company's talcum powder.

Evening Standard

Thousands of women plan legal action over alleged links between talc and cancer

If the action goes ahead it is understood to be the first of its kind against Johnson & Johnson in the UK.

The Guardian - US

Same-sex couple calls for protest after Washington eatery refuses to cater their wedding

JJ’s owner tells Rayah Calkins and fiancee Lillian Glover that the restaurant ‘stands by one thing only – the word of God’

Top News

Johnson & Johnson Subsidiary Files For Bankruptcy For Third Time

Johnson & Johnson subsidiary files for bankruptcy to settle talc-related cancer lawsuits. Proposed billion settlement faces legal challenges.

International Business Times

J&J CEO Slams Biden's Drug Pricing Law, Says It Will 'Chill' Innovation

J&J CEO explained that the new drug-price negotiation law threatens development of new drugs, according to Bloomberg.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the World Health Organization

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.